DNA testing service 23andMe filed for bankruptcy protection in March, raising alarms about the privacy of its 15 million customers' genetic data. In May, pharmaceutical company Regeneron purchased 23andMe for $256 million, promising to uphold privacy practices while utilizing the data for drug discovery. Amidst this shuffle, 1.9 million customers, approximately 15% of the user base, sought data deletion. More than two dozen states have sued to enforce explicit consent requirements for data transactions, prompting customers to take action to manage their data amidst ongoing legal scrutiny regarding the sale.
Pharmaceutical giant Regeneron announced in May that it was buying the genetic testing company for $256 million following a bankruptcy auction.
After 23andMe filed for bankruptcy, about 15% of its customer base has requested to delete their genetic data, raising concerns about privacy.
Collection
[
|
...
]